Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by cartach13on Apr 08, 2010 1:05pm

470 Views

Post# 16970385

RE: RE: Publication of Preclinical Research

Whatever,the SP is up 10 cents at last reading and the only news is today's. Could it be that there is a whole bunch of investors out there both retail and institutional who have their tongues hanging out for good news and are ready to pounce on that and purchase more shares? In any case it's up to Brad to promote the benefits of ONC ownership and maximize the SP. Get on with it Brad!

Bullboard Posts

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project